Patents by Inventor H. Dalton King

H. Dalton King has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 5708146
    Abstract: Provided are drug/ligand compounds of Formula (I): ##STR1## (I) in whichD is a drug moiety;n is an integer from 1 to 10;p is an integer from 1 to 6;Y is O or NH.sub.2.sup.+ C1.sup.- ;z is 0 or 1;q is about 1 to about 10;X is a ligand; and,A is a Michael Addition Adduct.In a preferred embodiment, the ligand is an immunoglobulin, preferably a chimeric antibody or fragment thereof. Also provided are formulations comprising as an active ingredient a compound of Formula (I), intermediates useful for preparing the compounds of Formula (I), processes for preparing the compounds of Formula (I), and methods for using the compounds of the invention.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: January 13, 1998
    Assignee: Bristol-Myers Squibb Company
    Inventors: David Willner, Pamela A. Trail, H. Dalton King, Sandra J. Hofstead, Robert S. Greenfield, Gary R. Braslawsky
  • Patent number: 5622929
    Abstract: Provided are drug/ligand compounds of Formula (I): ##STR1## in which D is a drug moiety;n is an integer from 1 to 10;p is an integer from 1 to 6;Y is O or NH.sub.2.sup.+ C1.sup.- ;z is 0 or 1;q is about 1 to about 10;X is a ligand; and,A is a Michael Addition Adduct.In a preferred embodiment, the ligand is an immunoglobulin, preferably a chimeric antibody or fragment thereof. Also provided are formulations comprising as an active ingredient a compound of Formula (I), intermediates useful for preparing the compounds of Formula (I), processes for preparing the compounds of Formula (I), and methods for using the compounds of the invention.
    Type: Grant
    Filed: January 23, 1992
    Date of Patent: April 22, 1997
    Assignee: Bristol-Myers Squibb Company
    Inventors: David Willner, Pamela A. Trail, H. Dalton King, Sandra J. Hofstead, Robert S. Greenfield, Gary R. Braslawsky
  • Patent number: 5606017
    Abstract: Provided are drug/ligand compounds of Formula (I): ##STR1## in which D is a drug moiety;n is an integer from 1 to 10;p is an integer from 1 to 6;Y is O or NH.sub.2.sup.+ Cl.sup.- ;z is 0 or 1;q is about 1 to about 10;X is a ligand; and,A is a Michael Addition Adduct.In a preferred embodiment, the ligand is an immunoglobulin, preferably a chimeric antibody or fragment thereof. Also provided are formulations comprising as an active ingredient a compound of Formula (I), intermediates useful for preparing the compounds of Formula (I), processes for preparing the compounds of Formula (I), and methods for using the compounds of the invention.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: February 25, 1997
    Assignee: Bristol-Myers Squibb Company
    Inventors: David Willner, Pamela A. Trail, H. Dalton King, Sandra J. Hofstead, Robert S. Greenfield, Gary R. Braslawsky
  • Patent number: 5162512
    Abstract: Novel antineoplastic amine-containing derivatives and methods for synthesizing such derivatives of anthracycline antibiotics are disclosed. The derivatives are useful to anthracycline antibiotic conjugates which retain substantial immunospecificity of the unconjugated antibody molecule. Using the conjugates, targeted delivery of the attached antibiotics is achieved in vivo. Such conjugates are thus therapeutically effective against a variety of neoplastic cellular disorders when administered in vivo. Methods for preparing the antibody conjugates and for use of the conjugates in vivo are also disclosed.
    Type: Grant
    Filed: May 27, 1988
    Date of Patent: November 10, 1992
    Assignee: Cytogen Corporation
    Inventors: H. Dalton King, Anthony D. Lopes, Robert D. Radcliffe, John D. Rodwell, Daniel J. Coughlin
  • Patent number: 4950738
    Abstract: Novel antineoplastic amine-containing derivatives and methods for synthesizing such derivatives of anthracycline antibiotics are disclosed. The derivatives are useful to prepare site-selectively attached therapeutic antibody-anthracyline antibiotic conjugates which retain substantial immunospecificity of the unconjugated antibody molecule. Using the conjugates, targeted delivery of the attached antineoplastic amine derivatives of anthracycline antibiotics is achieved in vivo. Such conjugates are thus therapeutically effective against a variety of neoplastic cellular disorders when administered in vivo. Methods for preparing the antibody conjugates and for use of the conjugates in vivo are also disclosed.
    Type: Grant
    Filed: June 5, 1987
    Date of Patent: August 21, 1990
    Assignee: Cytogen Corporation
    Inventors: H. Dalton King, Anthony D. Lopes, Robert D. Radcliffe, John D. Rodwell, Daniel J. Coughlin